CLINICAL TRIALS PROFILE FOR TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
✉ Email this page to a colleague
All Clinical Trials for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01949337 ↗ | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | Active, not recruiting | Astellas Pharma US, Inc. | Phase 3 | 2014-01-22 | This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body. |
NCT01949337 ↗ | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | Active, not recruiting | Biologics, Inc. | Phase 3 | 2014-01-22 | This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body. |
NCT01949337 ↗ | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | Active, not recruiting | Medivation, Inc. | Phase 3 | 2014-01-22 | This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body. |
NCT01949337 ↗ | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | Active, not recruiting | National Cancer Institute (NCI) | Phase 3 | 2014-01-22 | This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body. |
NCT01949337 ↗ | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | Active, not recruiting | Alliance for Clinical Trials in Oncology | Phase 3 | 2014-01-22 | This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body. |
NCT02304757 ↗ | 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis | Completed | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | N/A | 2015-01-01 | Postmenopausal women with differentiated thyroid cancer (DTC) taking suppressive doses of levothyroxine (L-T4) are thought to have accelerated bone loss and increased risk of osteoporosis. Therefore, the investigators try to investigate the effects of 99Tc-MDP,alendronate sodium in postmenopausal women with DTC under TSH suppression and osteoporosis. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Condition Name
Condition Name for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT | |
Intervention | Trials |
Adenocarcinoma of the Prostate | 1 |
Arthritis, Psoriatic | 1 |
Differentiated Thyroid Cancer | 1 |
Hormone-resistant Prostate Cancer | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Trials by Country
Clinical Trial Progress for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Clinical Trial Phase
Clinical Trial Sponsors for TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Sponsor Name